Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Bausch confirms infections in Europe; worries grow

May 4, 2006

By Julie Steenhuysen

CHICAGO (Reuters) – Bausch & Lomb Inc., under pressure
since authorities said its contact lens care products may be
linked to a spate of serious eye infections in Asia and the
United States, on Thursday said a “handful” of cases of the
infection have also been confirmed in Europe.

But the company, whose shares fell 6 percent to hit an
almost three-year low, refuted analyst questions that a large
debt buyback announced on Wednesday could leave it strapped for
cash.

Bausch & Lomb, based in Rochester, New York, last month
voluntarily recalled one of its ReNu lens care products in the
United States after some users were diagnosed with a rare but
serious fungal infections.

Harris Nesbitt analyst Joanne Wuensch said the European
cases raise new questions about the already-beleagured company.

“They just can’t get ahead of it,” Wuensch said.

The stock, which is trading near three-year lows, has
fallen nearly 40 percent this year and is the weakest
health-care issue in the Standard & Poor’s 500 index.

Health authorities have not yet determined a root cause of
the fungal infection, known as Fusarium keratitis, which can
lead to blindness and potential eye loss.

However, a large percentage of U.S. patients with the
infection were users of Bausch & Lomb lens solutions.

The company last month stopped shipping ReNu with
MoistureLoc and later advised retailers to remove the contact
lens solution from store shelves.

A report from the U.S. Centers for Disease Control and
Prevention issued this week found that 27 percent of confirmed
cases involved another ReNu brand, ReNu MultiPlus, suggesting
the company’s entire ReNu franchise may be at risk, analysts
said on Wednesday.

Kristen Foster, a spokeswoman for the company, confirmed
that the infection is now under investigation in Europe and
noted that a certain number of cases of the infection occur
routinely.

“The confirmed cases under investigation do not indicate
that there is an unusual trend,” Foster said.

Bausch & Lomb said its products in Europe include ReNu with
MoistureLoc and ReNu MultiPlus.

Authorities in Singapore had earlier linked a number of
cases of the same infection to use of Bausch & Lomb ReNu
solution, and Hong Kong had asked the company to pull ReNu from
store shelves, although testing did not show a problem.

TOO MUCH TO PAY?

Concerns that the infection may also be affecting people in
Europe comes amid questions about the company’s cash position
after a large debt repurchase.

Bausch late on Wednesday said it was offering to repurchase
all of five series of bonds totaling nearly $544 million in
principal.

In a note to clients, Banc of America Securities analyst
David Maris said it appeared that Bausch is offering to
repurchase the debt at a very expensive price.

Maris speculated that the debt buyback might be driven by
possible expectations the company may further delay filing
financial reports with regulators.

Maris said Bausch may be looking to reduce any bondholder
leverage if it defaults on its debt.

“We believe after tendering the debt, (it) will be left
with little cash, the looming ReNu situation, and an unknown
potential medical legal liability.”

But a Bausch & Lomb spokesman said the company has ample
cash to cover its debt repurchase, which he said was not
initiated at the urging of a bondholder.

“I think at the end of the day we were pretty clear. We are
tendering these because it was a stated corporate goal. We have
more than enough cash even if everyone tenders,” said Dan Ritz,
Bausch & Lomb’s director of investor relations.

Ritz said the company also has no borrowings under its $400
million revolving credit facility, which also could be used as
a source of cash.

Bausch & Lomb has delayed the filing of its 2005 10-K
annual report as it tries to resolve tax issues and other
improper behavior at subsidiaries in Brazil and Korea.

LAWSUITS BUILDING

Most analysts have yet to quantify Bausch & Lomb’s
potential liability if scientists directly link the infection
outbreak with the company’s products.

Cal Warriner, a West Palm Beach attorney who represents a
69-year-old woman who lost her left eye to Fusarium keratitis
and is suing Bausch & Lomb, said the number of cases against
the company is growing.

“We’re getting phone calls fast and furious,” Warriner
said. “Originally, it appeared it was a contaminant issue, and
now it appears the scope of the inquiry is broadening. People
are now looking at the entire ReNu line.”

His firm now more than 100 cases against Bausch & Lomb.

The stock was off $2.78 to $41.19 on the New York Stock
Exchange.

(Additional reporting by Daniel Burns and Anna Driver in
New York)


Source: reuters